



Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 05:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240033815



Page 1 of 14





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM

Reported : 10/Feb/2024 05:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	14.1	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	42.80	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.44	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	96.4	fL	83-101	Calculated
MCH	31.7	pg	27-32	Calculated
MCHC	32.9	g/dL	31.5-34.5	Calculated
R.D.W	14.1	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,410	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	IT (DLC)			·
NEUTROPHILS	48.1	%	40-80	Electrical Impedance
LYMPHOCYTES	40.6	%	20-40	Electrical Impedance
EOSINOPHILS	4.9	%	1-6	Electrical Impedance
MONOCYTES	5.4	%	2-10	Electrical Impedance
BASOPHILS	1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2602.21	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2196.46	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	265.09	Cells/cu.mm	20-500	Calculated
MONOCYTES	292.14	Cells/cu.mm	200-1000	Calculated
BASOPHILS	54.1	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	195000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	06	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE. NO HEMOPARASITES SEEN

Page 2 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240033815





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 05:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240033815







Age/Gender : 41 Y 10 M 14 D/M
UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM Received : 10/Feb/2024 10:32AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 11:53AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA			
BLOOD GROUP TYPE	A			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 12:41PM

Received : 10/Feb/2024 01:34PM Reported : 10/Feb/2024 04:49PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	102	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	99	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 12:38PM Reported : 10/Feb/2024 01:32PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN), I	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- $5.\ In\ cases\ of\ Interference\ of\ Hemoglobin\ variants\ in\ HbA1C, alternative\ methods\ (Fructosamine)\ estimation\ is\ recommended\ for\ Glycemic\ Control$

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240014957

Page 6 of 14







Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE , SERUM	'		1	
TOTAL CHOLESTEROL	183	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	151	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	48	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	135	mg/dL	<130	Calculated
LDL CHOLESTEROL	104.8	mg/dL	<100	Calculated
VLDL CHOLESTEROL	30.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.81		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

telefone interval as per reactional endesteror Education Program (NeEl) Feduci Frederick Famer in Report.						
	Desirable	Borderline High	High	Very High		
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240			
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500		
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190		
HDL	≥ 60					
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220		

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 14



Dr. SHWETA GUPTA
MBBS, MD (Pathology)
Consultant Pathology
SIN No:SE04625400





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT) , SERUM		'	1	
BILIRUBIN, TOTAL	0.90	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	25	U/L	<50	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	28.0	U/L	17-59	UV with P-5-P
ALKALINE PHOSPHATASE	84.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.70	g/dL	6.3-8.2	Biuret
ALBUMIN	4.10	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.60	g/dL	2.0-3.5	Calculated
A/G RATIO	1.14		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM							
CREATININE	0.80	mg/dL	0.66-1.25	Creatinine amidohydrolase			
UREA	29.40	mg/dL	19-43	Urease			
BLOOD UREA NITROGEN	13.7	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	5.50	mg/dL	3.5-8.5	Uricase			
CALCIUM	9.70	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	4.10	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	136	mmol/L	135-145	Direct ISE			
POTASSIUM	4.3	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	100	mmol/L	98 - 107	Direct ISE			

Page 9 of 14









Age/Gender : 41 Y 10 M 14 D/M

UHID/MR No : SCHI.0000017947 Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:30AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	18.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 10 of 14



Dr. SHWETA GUPTA
MBBS, MD (Pathology)
Consultant Pathology
SIN No:SE04625400





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 12:58PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSF	l), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.07	ng/mL	0.67-1.81	ELFA
THYROXINE (T4, TOTAL)	7.05	μg/dL	4.66-9.32	ELFA
THYROID STIMULATING HORMONE (TSH)	1.770	μIU/mL	0.25-5.0	ELFA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 12:55PM Reported : 10/Feb/2024 01:55PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
TOTAL PROSTATIC SPECIFIC ANTIGEN (tPSA), SERUM	0.930	ng/mL	0-4	CLIA

Page 12 of 14







Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM Received : 10/Feb/2024 11:49AM

Reported : 10/Feb/2024 04:55PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				·
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	′		
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-2	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:UR2279769

Page 13 of 14





: DETJUXYFG

Age/Gender : 41 Y 10 M 14 D/M

UHID/MR No : SCHI.0000017947 Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID

Collected : 10/Feb/2024 10:11AM Received : 10/Feb/2024 11:50AM

Reported : 10/Feb/2024 04:57PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick
				·
Test Name	Result	Unit	Bio. Ref. Range	Method

Test Name Result Unit Bio. Ref. Range Method
URINE GLUCOSE(FASTING) NEGATIVE NEGATIVE Dipstick

*** End Of Report ***

Page 14 of 14





Patient Name : Mr. DEVENDER KUMAR Age : 41 Y/M

UHID : SCHI.0000017947 OP Visit No : SCHIOPV25911

Conducted By: : Conducted Date :

Referred By : SELF

Patient Name : Mr. DEVENDER KUMAR Age : 41 Y/M

UHID : SCHI.0000017947 OP Visit No : SCHIOPV25911

Conducted By : Conducted Date :

Referred By : SELF



Name : Mr. DEVENDER KUMAR

Age: 41 Y

Sex: M

UHID:SCH1.0000017947

Plan	: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN INDIA OP AGREEMENT	x: M	OP Number: SCHIOPV25911 Bill No : SCHI-OCR-9352 Date : 10.02.2024 10:04
Sno	Serive Type/ServiceName		Department
1	GAMMA GLUTAMYL TRANSPIRATE GOTT	E 50Y MA	LE - TMT - PAN INDIA - EV2324
	THE TRANFERASE (GGI)		11.001
2	PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)		
.3	LIVER FUNCTION TEST (LFT)		
	GLUCOSE, FASTING -		
	HEMOGRAM + PERIPHERAL SMEAR		
	DIET CONSULTATION		
	COMPLETE URINE EXAMINATION		The state of the s
8	URINE GLUCOSE(POST PRANDIAL)		
	PERIPHERAL-SMEAR		
	ECG 200		
11	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)		
	DENTAL CONSULTATION V		
13	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)		
14	URINE GLUCOSE(FASTING)		
	HbA1c, GLYCATED HEMOGLOBIN		
-	X-RAY CHEST PA		
	ENT CONSULTATION		
18 (CARDIAC STRESS TEST(TMT)		
19 F	FITNESS BY GENERAL PHYSICIAN		
20 E	BLOOD GROUP ABO AND RH FACTOR		
	JPID PROFILE		
	SODY MASS INDEX (BMI)		
23 C	PTHAL BY GENERAL PHYSICIAN		
	LTRASOUND - WHOLE ABDOMEN 1		
25 T	HYROID PROFILE (TOTAL T3, TOTAL T4, TSH)		

Booking ID	EMP-NAME	AGE	GENDER
bobS7423	REKHA	35 year	Female
bobE7422	MR. KUMAR DEVENDER	41 year	-

Licence to Draw Vehicles Throughout India

Licence to Draw Vehicles

Licence to

(S2) WinosituA galutal

•



DIGITAL X-RAY REPORT

NAME: DEVENDER	DATE: 10.02.2024
UHID NO: 17947	AGE: 41YRS/ SEX: M

X-RAY CHEST PA VIEW

Fibrotic opacities are seen at right hila, left upper zones

Rest of the lung fields show accentuated bronchovascular markings

Nodule seen in right lower zone

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA

TOU ALL

Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Patient ID: 17947 10.02.2024

Male 168 cm 67 kg 41 yrs Indian

GE CardioSoft V7/0(10) 25 mm/s 10 mm/mV 0.04-150/Hz 50 Hz 12SL V23 Vent. Rate PR interval Sokolow-Lyon P-R-T axes QT/QTe(B) RR / PP interval P duration **QRS** duration 66/69/620 816/810 ms 1.34 mV 352 / 390 ms 86 ms 74 bpm 122 ms 82 ms Normal Sinus rhythm Normal ECG Arrhythmia results of the full-disclosure ECG-QRS Complexes: 24 System Evaluation: Location: * 0 * aVL Unconfirmed 1 V2 T.Z. Attending MD: Page 1



NAME:	DEVENDER KUMAR	AGE/SEX:	41	YRS./M
UHID:	17947			
REF BY:	APOLLO SPECTRA	DATE:-	10.02.	2024

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse.lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder; is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Prostate: normal in size, weight 17 Gms. It is normal in echotexture with no breech in the capsule.

No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab. Investigations.

DR. PRADEEP DUFTA Consultant Radiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



Patient Name

Mr. DEVENDER KUMAR

UHID

SCHL0000017947

Conducted By: Referred By Dr. MUKESH K GUPTA SELF Age

OP Visit No Conducted Date 41 Y/M

: SCHIOPV25911

10-02-2024 17:47

Protocol Medication Bruce Protocol

Target Heart Rate

179 BPM 173 BPM

Heart Rate Achieved Percentage of THR Achieved Maximum Blood Pressure

96% 130/84 mmHg

Maximum Blood Pressure Total Exercise Duration Maximum Worked Attained Reason for termination

09:03 Min 10:10 Mets Max HR attained

Comments

- Basal ECG NSR.
- Appropriate HR response
- Appropriate BP response.
- No significant changes with standing and hyperventilation.
- Good exercise tolerance.
- No significant ST segment depression over baseline during exercise or recovery period.
- · No crepts or rhonchi
- Arrhythma none.
- · Chest pain absent.

Summary

- Test is negative for provocable myocardial ischemia.
- Good exercise tolerance.
- Appropriate BP response.

Please correlate clinically Not valid for medico legal purpose.

Dr. M K Gupta M.H.B.S, MD,FIACM Senior Consultant Cardiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

								Page 1/
APOLLO SPEC	TDA		шшы			Station		
NEHRU ENCL						Telephone	e:	
	AVE							
NEW DELHI								
		EX	ERCIS	E STI	RESS	TEST	REPORT	
Patient Name: K	TIMAR DEVE	NDER			DOB:	27.03.1982		
Patient ID: 1794		115,557			Age: 4	Lyrs		
Height: 168 cm						r: Male		
Weight: 67 kg					Race:	Indian		
Study Date: 10.	02 2024				Referr	ing Physicia	m:	
Test Type:	V-18YF				Attend	ing Physicia	an:	
Protocol: BRUC	CE				Techn	ician:		
4.4.145								
Medications:								
Medical History	y:							
**								
Reason for E	xercise Test:							
**								
Exercise Tes	t Summary							
Lacreise res	1 Summur 2							
Phase Name	Stage Name	Time	Speed	Grade	HR	BP	Comment	
		in Stage	[mph]	[70]	[bpm]	[mmHg]		
PRETEST	SUPINE	00:46	0.00	0.00	71	110/70		
	STANDING	01:15	0.00	0,00	82	110/70		
	WARM-UP	00:19	0.70 1.70	10.00	88 123	120/80		
EXERCISE	STAGE 1	03:00	2.50	12.00	150	124/84		
	STAGE 2 STAGE 3	03:00	3.40	14.00	173	124/84		
	STAGE 4	00:03	3.20	14,30	171	0.72 0.00		
RECOVERY	510) 520 C/2	02:57	0.00	0.00	109	120/80		
The mariner	avaraisad noo	ording to t	he BRI (F for	9:03 m	in:s achie	eving a work level o	of Max. METS: 10.
The patient of	exercised acc	71 hom to	ne to a m	avimal	heart	ate of 173	bpm. This value re	presents 96 % of t
The resting	heart rate of	d ppm ro	se to a th	axiillai	d assess	are of 116)/70 mmHa rose to	ya maximum blood
maximal, ag	e-predicted h	eart rate.	he restir	ig bloo	d press	ure of 110	0/70 mmHg, rose to	, a maximum oroso
pressure of	130/84 mmH	g. The exe	rcise test	was sto	opped	due to Ma	x HR attained.	
Interpretatio								
merpretatio	***							
Summary: R	Resting ECG:	normal.						
	Capacity: nor							
HR Respons	se to Exercise	appropri	ate,					
BP Respons	e to Exercise	normal re	esting BP	- appr	opriate	response		
Chest Pain:	none.							

Technician

Conclusions

Physician_

ason: I-History:					Unconfirmed	Unc			V/.0(10)	GE CardioSoft V / 0 (10)
Male 168 cm 67 kg Male 197 kg Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 Max RPP 22230 m Max BP 13084 mmlg Bar lext 11070 mmlg Par lext 11070 mm									2000	
Male 168 cm 67 kg Male 183 cm 194 yrs Indian Make IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R at rest: 7 Max IR: 179 m 96 % of may predicted 179 bpm 14R level 27 m 18 m 19										
Male 168 cm 67 kg May 181 715 hpm 36% of max predicted 179 bpm 11R at rest. 7 Max 181 715 hpm 36% of max 181 EXERCISE 340 npm 36% of max 181										
Make 168 cm 67 kg Makar HE, 715 kpm 56% of max predicted 179 kpm HR at rest. 7 Max HE, 715 kpm 56% of max predicted 179 kpm HR at rest. 7 Max HE, 715 kpm 56% of max predicted 179 kpm HR at rest. 7 Max HE, 715 kpm 56% of max predicted 179 kpm HR at rest. 7 Max SE, 205 kpm, 0.6 kpm at policy 100 METS Have the provided the provided HR at rest. 7 Max SE, 205 kpm, 0.6 kpm at policy 100 METS HR, rescovery 14 kpm										
Male 168 cm 67 kg 41 yrs Indian Macks: Max HE, 73 hpm 9, 96 of max predicted 179 hpm HR at rest. 7 Max HE, 73 hpm 9, 96 of max predicted 179 hpm HR at rest. 7 Test Reason: Test Reason: Max MP: 13084 mmHg BP at rest 10,70 Max RPP: 22230 mm Max MP: 13084 mmHg BP at rest 10,70 Max RPP: 22230 mm Max MP: 13084 mmHg BP at rest 10,70 Max RPP: 22230 mm Max MP: 13084 mmHg BP at rest 10,70 Max RPP: 22230 mm Max MP: 13084 mmHg BP at rest 10,70 Max RPP: 22230 mm Max MP: 13084 mm Go in Wis in II; EXERCISE STAGE 3 9,00 Max SP: 13084 mm Go in Wis in II; EXERCISE STAGE 3 9,00 Max Mp: 13084 mm Go in Wis in II; EXERCISE STAGE 3 9,00 Max Mp: 13084 mm Go in Wis in II; EXERCI										
Made: 168 cm 67 kg 41 yrs Indian Meds: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest. 7 Max HR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 11070 Max RPP: 22230 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 3 9.00 Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 3 9.00 Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 3 9.00 Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 3 9.00 Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; EXERCISE STAGE 92 m Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; Inm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; Inm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; Inm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 0 of mVs in III; Inm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] III Inm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] III Inm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] Max MR: 13084 mmHg BP at rest. 1070 mm 1] Max MR: 13084 mmHg BP at r										
Makels: Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm 96% of max predicted										
Make 168 cm 67 kg 41 yrs Indian Makels: Max HR: 173 bpn 96% of max predicted 179 bpm HR at rest: 7 Max BP: 13084 mmltig BP at rest: 10070 Mix RPP: 22230 m Maximum Workland: A.3.1, VBIC2, PVC.96, CPLT2, PCAP-1 STIFR indican: Test Type: Comment: Comment: Test Type: Comment: Test Type: Comment: Test Type: Speed Grade Speed Grade Workload HR BP RPP RPP RPP VE STILENE Comment: Time Speed Grade Speed Grade Workload HR RPP RPP VE STILENE Comment: Time Speed Grade Speed Grade Workload HR RPP RPP VE STILENE Comment: Resonor: Resonor:										
Made: 168 cm 67 kg Male: 168 cm 67 kg Maximum Weds: 71 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max HR: 173 bpm HR: 173 bpm 96% of max predicted 179 bpm HR: 173 bpm 96% of max predicted 179 bpm HR: 173 bpm 96% of max predicted 179 bpm HR: 173 bpm 96% of max HR: 173 bpm HR: 173 bpm 114 bpm HR: 173 bpm 114										
Made: 168 cm 67 kg 41 yrs Indian Meds: Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max Max Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max Max Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max hR at max predicted 179 bpm HR at rest: 17 Max HR: 173 bpm 96% of max hR: 111 bpm HR: 171 bpm 97% Max HR: 173 bpm 96% of max predicted 179 bpm HR: 171 bpm 97% Max HR: 173 bpm 96% of max predicted 179 bpm HR: 171 bpm 97% Max HR: 173 bpm 96% of max predicted 179 bpm HR: 171 bpm 97% Max HR: 173 bpm 97% Max HR: 17										
Male 168 cm 67 kg Mays Indian Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 1070 Max RPP: 22230 mt Max BP: 13084 mmHg BP at rest: 7084 mx Max										
Male 168 cm 67 kg Max BP 13084 mmlg BP at rest: 11070 Max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 Max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 Max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 Max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 Max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 max RPP 22230 ml Max BP 13084 mmlg BP at rest: 11070 mmlg Gr PVC-96. CPLT-2 PCAP-1 STARIBUTE STAGE 3 9.00 Max STI-J. 50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9.00 Max STI-J. 50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9.00 Max STI-J. 50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9.00 Max STI-J. 50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9.00 Max BP 13084 max BP at rest: 11070 mm, 0.61 mVs in III; EXERCISE STAGE 3 9.00 Max BP 13084 mmlg BP at rest: 11070 mmlg frequency in VEIND mmlg max III; EXERCISE STAGE 3 9.00 Max BP 13084 mmlg BP at rest: 11070 mmlg frequency in VEIND mmlg max III; EXERCISE STAGE 3 9.00 Max BP 13084 mmlg BP at rest: 11070 mmlg frequency in VEIND mmlg mmlg mmlg mmlg mmlg mmlg mmlg mml										
Male 168 cm 67 kg Male 168 cm 67 kg Male 181 in September 182 in Stage Name Time Speed Grade Workload HR Resone: Make BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mm Max BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mm Max BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mm Max BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mm Max BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mm Max BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mm Max BP: 13084 mml4g BP at rest: 11070 Max RPP: 22230 mml4g BP at rest: 12084 mml4g BP at rest: 11070 Max RPP: 22230 mml4g BP a										
Male 168 cm 67 kg Male 168 cm 67 kg Max H2: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max H2: 130 bpm 10 of Max H2: 100 max PP- VC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: A.31, VBBG2, PVC-96, CPLT:2, PCAP-1 STHR index: 0.40 aprophila: Arrival index: 0.40 aprophila: A			120/80	109	.0	000	0.00	02:57		RECOVERY
Male 168 cm 67 kg				171	0	14.30	3.20	00:03	STAGE 4	
Male 168 cm 67 kg May BRUCE: Exercise Time 09:03 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 11070 Max RPP: 22230 mt Max MR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 11070 Max RPP: 22230 mt Max BP: 130 84 mmHg BP at rest: 11070 Max RPP: 22230 mt Max BP: 130 84 mmHg BP at rest: 11070 Max RPP: 22230 mt Max BP: 130 84 mmHg BP at rest: 11070 Max RPP: 22230 mt Max BP: 130 84 mmHg BP at rest: 7 Max BP: 130 84 mmHg BP at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130 84 mmHg BP at rest: 100 Max RPP: 22230 mt Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of final ppm Max HR at rest: 100 METS 19 mm, of min Sign Predicted 179 bpm HR at rest: 100 mm of min Sign Predicted 179 bpm HR at rest: 100 mm of min Sign Predicted 179 bpm HR at rest: 100 mm of min Sign Predicted 179 bpm HR at rest: 100 mm of min Sign Predicted 179 bpm Max HR at rest: 100 mm of min Sign Predicted 179 bpm min Mg bpm of min Sign Predicted 179 bpm of min Sig			124/84	173	10.1	14.00	3,40	03.00	STAGE 3	
Male 168 cm 67 kg May 178 Indian Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 7 Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max Max MP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max Max MP: 130/84 mmHg BP at rest; 110/70 Max RPP; 2230 mt Max Max MP: 130/84 mmHg BP at rest; 110/70 Max Max MP; 120/84 mmHg BP; 120/84 m			124/84	150	7.0	12,00	2.50	03:00	STAGE 2	
Male 168 cm 67 kg Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 max PFA KEX: 90 ms, PFA KEX: 90 ms, PFA KEX: 90 ms, PFA KEX: 90 ms, REC 92 ms Max BR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 max PFA KEX: 90 ms, PFA KEX: 90 ms, PFA KEX: 90 ms, PFA KEX: 90 ms, REC 92 ms Max BP: 130/84 mmHg BP at rest: 110/70 max HR attained STHR hysteresis: -0.008 mV(V2) QRS duration: Max HR attained Summary: Resting ECG: normal. Functional Capacity: normal. HR Responsitions appropriate. BP Response to Exercise: normal resting BP: 4ppropriate. BP Respon			120/80	123	4.6	10.00	1.70	03:00	STAGE	EXERCISE
Maile 168 cm 67 kg			100000000000000000000000000000000000000	00 00	=	0.00	0.70	00:19	WARM-UP	
Make 168 cm 67 kg			110/70	82	1.0	0.00	0.00	01:15	STANDING	
Make 168 cm 67 kg Maker 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mm Max ST: -0.50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9:00 Arrhythmia: A31, VBIG: 2, PVC-96, CPLT: 2, PCAP: 1 Medical History: Max ST: -0.50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9:00 Arrhythmia: A31, VBIG: 2, PVC-96, CPLT: 2, PCAP: 1 Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 74 Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 110/70 max RPP; 22230 mm Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 110/70 max RPP; 22230 mm Max BP: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 110/70 max RPP; 22230 mm Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 110/70 max RPP; 22230 mm Max HR: 130/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 100/70 max RPP; 22230 mm Max HR: 173 bpm 96 % of max predicted 179 bpm Max RPP; 22230 mm Max HR: 120/84 mmHg BP ncceived: Max HR: 173 bpm 96 % of max predicted 179 bpm Arrhythmia Arrhythm		7810 0	110/70		1.0	0.00	0.00	00:46	SUPINE	PRETEST
Male 168 cm 67 kg Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 7 Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest; 7 Max BP: 13084 mmHg BP at rest; 11070 Max RPP; 22230 mm Max ST: 40.50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9:00 Max SP: 10.50 mm, 0.61 mVs in III; EXERCISE STAGE 3 9:00 Arrhythmia: A.31, VBIG:2, PVC-96, CPLT:2, PCAP:1 Ref. MD: Ordering MD: Technician: Test Type: Comment: Comment: Test Type: Comment: Time Speed Grade Workload HR BP RPP VE STLevel Comment Strukt and the time of		mmHg*bp [/m	[mmHg]	_	METS	[%]	[mph]	in Stage		
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Maximum Workload: 10.10 METS Test Reason: Medical History: Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3-9:00 Arrhythmia: A:31, VBIG:2, PVC-96, CPLT:2, PCAP:1 ST/HR index: 0.40 µV/bpm HR recovery: 48 bpm VE recovery: 14 VE/min VE recovery: 11 VE/min ST/HR hysteresis: -0.008 mV (V2) QRS duration: BASELINE: 90 ms, PEAK EX: 90 ms, REC: 92 ms Resting ECG: normal Functional Capacity: normal, HR Response to Exercise: normal resting BP- appropriate Room: Location: *0 *	STLevel		BP		Workload	Grade	Speed	Time	Stage Name	Phase Name
Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 7 Max HR at rest: 7 Max HR at rest: 7 Max HR at resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise: normal resting BP - ppropriate BP Response to Exercise normal resting BP - ppropriate		.0.	Location:							
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Maximum Workload: 10.10 METS Max. ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Arrhythmia. A.3.1, VBIG.2, PVC-96, CPLT-2, PCAP:1 ST/HR index: 0.40 µV/bpm HR recovery: 48 bpm VE recovery: 11 VE/min VE recovery: 12 VE/min VE recovery: 13 VE/min VE recovery: 14 VE/min VE re			Room:							
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 7 Max BP: 130/84 mmHg BP at rest: 10/70 max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 10/70 max RPP: 22230 mm Max BP: 130/84 mmHg BP at rest: 10/70 mmHg BP: 10/70 mmHg BP: 10/70 mmHg BP at rest: 7 Max BP: 130/84 mmHg BP: 130/84 mmHg BP: 10/70 mmHg BP		n: none.	Chest Pair							
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Maximum Workload: 10.10 METS Max. ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Max. ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: A:31, VBIG-2, PVC-96, CPLT-2, PCAP:1 ST/HR index: 0.40 µV/bpm HR reserve used: 92% Technician: Test Type: Comment: Comment: VE recovery: 14 8 bpm VE recovery: 14 VE/min VE recovery: 14 VE/min ORS duration: Max HR attained Summary: Resting FCC counts Functional Canacity: normal HR Reserve	to Exercise: normal resting BP - appropriate response.	BP Response i	appropriate							
Male 168 cm 67 kg Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Arrhydhmia: A:31. VBIG:2, PVC-96, CPLT:2, PCAP:1 Ref. MD: Ordering MD: SIT/HR index: 0.40 µV/bpm HR recovery: 14 Vbmin VE recovery: 11 Vbmin	netional Canacity normal HR Response to Exercise	C-norms Fun	Bosting F							
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Meds: Meds: Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Medical History: Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: A:31, VBIG:2, PVC-96, CPLT:2, PCAP:1 ST/HR index: 0.40 µV/bpm HR reserve used: 92.% HR recovery: 148 bpm VE recovery: 14 bpmin VE recovery: 11 VE/min VE recovery: 11 VE/min VE recovery: 11 VE/min VE recovery: 11 VE/min VE Reserve used: 90 ms, PEAK EX: 90 ms, REC: 92 ms	: Max HK attained	or Termination:	Reasons to							
Male 168 cm 67 kg May HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max maximum Workload: 10.10 METS Max. ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Medical History: Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max BP: 130	2 90 ms, PEAN EX: 90 ms, NEC: 92 ms	IOII: BASELINE:	QKS durat							
Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Anthythmia: A-31, VBIG-2, PVC-96, CPLT-2, PCAP:1 Ref. MD: Ordering MD: Technician: Test Type: HR reserve used: 92 % HR recovery: 14 VE min VE recovery: 11 VE min	IN (YZ)	ileresis -u.uua m	SUHKRY							
Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mt Max ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: A:31, VBIG:2, PVC-96, CPLT:2, PCAP:1 Ref. MD: Ordering MD: Ref. MD: Ordering MD: HR reserve used: 92 % HR reserve used: 92 % HR reserve used: 92 %		ry: II Viciniin	VE recove						Comment:	
Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Meds: Meds: Meds: Test Reason: Medical History: Medical History: Medical History: Medical History: Medical History: Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22		ry: 48 bpm	HR recove					Test Type:	Technician:	
Male 168 cm 67 kg Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Meds: Medical-History: Max BR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Max BP: 130/84 mmHg BP at rest: 10/70 Max RPP: 22230 mu Arrhythmia: 0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: 0.40 m/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: 0.40 m/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: 0.40 m/s in III; EXERCISE STAGE 3 9:00 Arrhythmia: 0.40 m/s in III; EXERCISE STA		used: 92 %	HR reserve					rdering MD:		
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest; 7 41 yrs Indian Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Medical History: Medical History: Max BR: 173 bpm 96% of max predicted 179 bpm HR at rest; 7 Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP at rest; 7 Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Max BP: 130/84 mmHg BP		ex: 0.40 µV/bpm	ST/HR ind						100000000000000000000000000000000000000	
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest; 7 41 yrs Indian Max BP: 130/84 mmHg BP at rest; 110/70 Max RPP: 22230 mt Meds: Maximum Workload: 10.10 METS Max. ST: -0.50 mm, 0.61 mV/s in III; EXERCISE STAGE 3 9:00	2. PVC-96. CPLT-2. PCAP-1	a: A:31. VBIG:2	Arrhythmi					VPU-	Medical Histo	
Male 168 cm 67 kg Max HR: 173 bpm 96% of max predicted 179 bpm HR at rest: 7 H yrs Indian Max BP: 130/84 mmHg BP at rest: 110/70 Max RPP: 22230 mu Meds: Maximum Workload: 10.10 METS	mV/s in III; EXERCISE STAGE 3 9:00	0.50 mm, 0.61 m	Max. ST:-						Test Reason:	
Male 168 cm 67 kg BRUCE: Exercise Time 09:03 Max HR: 173 bpm 96 % of max predicted 179 bpm HR at rest: 7 Max RP: 130/84 mmHa RP at rest: 110/70 Max RPP: 22230 mm	0 METS	Workload: 10.10	Maximum						Meds:	
Male 168 cm 67 kg BRUCE: Exercise Time 09:03	01 max predicted 179 opin - Fix of test, 71 RP at roct - 110/70 - Max RPP: 22230 mmHe*bom	30/84 mmHo B)	May RP-1						41 yrs Indian	2:41:08pm
	9:03	xercise lime 09:	BRUCE: E					67 kg	Male 168 cm	10.02.2024
									47	Patient ID: 179

Exercise Test / Tabular Summary

CERTIFICATE OF MEDICAL FITNESS

This is to certify that I have conducted the clinical examination

e	Medically Fit
	Fit with restrictions/recommendations
	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.
	1
	2
	3
	However the employee should follow the advice/medication that has been communicated to him/her.
	Review after
	Currently Unfit.

Dr. Medical Officer
The Apollo Clinic, Uppal

This certificate is not meant for medico-legal purposes

PREVENTIVE HEALTH CARE SUMMARY

NIABAR		11001	THE TAIL
NAME :- Deve	ndes	UHID No:	170
AGE/GENDER :-	(1), 10	RECEIPT	1 1 1
PANEL:	Harlow		
	- cotour!	EXAMINEI	ON:- 0
		RI.	
		90	
Chief Complaints:	N	D Su. 1 14	1
		augh ce r	10
			(-
Past History:			
DM .			
Hypertension	Wil	CVA .	- NIL
CAD	INIT	Cancer .	Nie
:	Nil	Other .	Nil
Personal History:		•	NII
Alcohol .	1		
Smoking	Nil	Activity :	-Active
	Con	Allergies :	NH
Family History: DM	IMT		
General Physical Exami	ination:		
Height \68.	and the second	211	
Weight		Pulse & /m	bpm
6-7.	Ngs	BP (mmHe
Rest of examination was v	NDER: PLOYER RECEIPT No: - PLOYER RECEIPT No: - PROJECT RECEIPT NO		
Systemic Examination:			
CVS .			
Respiratory system			
Abdominal system			
CNS	A STATE OF THE STA		
Others :	C-CEPPOLITE		
	Normal		

PREVENTIVE HEALTH CARE SUMMARY

NAME: - Deven	der	UHID No:	
AGE :- S	EX:	RECEIPT No : -	
PANEL:		EXAMINED ON : -	

Investigations:

All the reports of tests and investigations are attached herewith

T9 151

Recommendation:

· low fat dut
Cap a Active once a day x1-2 month
My vite D3 60 konce a week
6-12 week

Dr. Navneet Kaur Consultant Physician Patient Name : Mr. DEVENDER KUMAR Age : 41 Y/M

UHID : SCHI.0000017947 OP Visit No : SCHIOPV25911 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 10-02-2024 17:50

Referred By : SELF

Protocol : Bruce Protocol

Medication :

Target Heart Rate:179 BPMHeart Rate Achieved:173 BPMPercentage of THR Achieved:96%

Maximum Blood Pressure: 130/84 mmHgTotal Exercise Duration: 09:03 Min.Maximum Worked Attained: 10.10 MetsReason for termination: Max HR attained.

Comments

- Basal ECG NSR.
- Appropriate HR response.
- Appropriate BP response.
- No significant changes with standing and hyperventilation.
- Good exercise tolerance.
- No significant ST segment depression over baseline during exercise or recovery period.
- No crepts or rhonchi.
- Arrhythmia none.
- Chest pain absent.

Summary

- Test is negative for provocable myocardial ischemia.
- Good exercise tolerance.
- Appropriate BP response.

Please correlate clinically

Not valid for medico legal purpose.

Dr. M K Gupta M.B.B.S, MD,FIACM Senior Consultant Cardiologist Patient Name : Mr. DEVENDER KUMAR Age : 41 Y/M

UHID : SCHI.0000017947 OP Visit No : SCHIOPV25911 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 10-02-2024 17:50

Referred By : SELF





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 05:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240033815



Page 1 of 14





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM

Reported : 10/Feb/2024 05:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	14.1	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	42.80	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.44	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	96.4	fL	83-101	Calculated
MCH	31.7	pg	27-32	Calculated
MCHC	32.9	g/dL	31.5-34.5	Calculated
R.D.W	14.1	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,410	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	IT (DLC)			·
NEUTROPHILS	48.1	%	40-80	Electrical Impedance
LYMPHOCYTES	40.6	%	20-40	Electrical Impedance
EOSINOPHILS	4.9	%	1-6	Electrical Impedance
MONOCYTES	5.4	%	2-10	Electrical Impedance
BASOPHILS	1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2602.21	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2196.46	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	265.09	Cells/cu.mm	20-500	Calculated
MONOCYTES	292.14	Cells/cu.mm	200-1000	Calculated
BASOPHILS	54.1	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	195000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	06	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE. NO HEMOPARASITES SEEN

Page 2 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240033815





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 05:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240033815







Age/Gender : 41 Y 10 M 14 D/M
UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM Received : 10/Feb/2024 10:32AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 11:53AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA							
BLOOD GROUP TYPE	A			Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 4 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 12:41PM

Received : 10/Feb/2024 01:34PM Reported : 10/Feb/2024 04:49PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	102	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	99	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 12:38PM Reported : 10/Feb/2024 01:32PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
HBA1C (GLYCATED HEMOGLOBIN), WHOLE BLOOD EDTA					
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC	
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated	

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- $5.\ In\ cases\ of\ Interference\ of\ Hemoglobin\ variants\ in\ HbA1C, alternative\ methods\ (Fructosamine)\ estimation\ is\ recommended\ for\ Glycemic\ Control$

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240014957

Page 6 of 14







Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
LIPID PROFILE , SERUM							
TOTAL CHOLESTEROL	183	mg/dL	<200	CHE/CHO/POD			
TRIGLYCERIDES	151	mg/dL	<150	Enzymatic			
HDL CHOLESTEROL	48	mg/dL	>40	CHE/CHO/POD			
NON-HDL CHOLESTEROL	135	mg/dL	<130	Calculated			
LDL CHOLESTEROL	104.8	mg/dL	<100	Calculated			
VLDL CHOLESTEROL	30.2	mg/dL	<30	Calculated			
CHOL / HDL RATIO	3.81		0-4.97	Calculated			

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

Activities interval as per reactional enviseror Education Program (1962) Padate Production Patricipals.					
	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 14



Dr. SHWETA GUPTA
MBBS, MD (Pathology)
Consultant Pathology
SIN No:SE04625400





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
IVER FUNCTION TEST (LFT) , SERUM							
BILIRUBIN, TOTAL	0.90	mg/dL	0.20-1.20	DIAZO METHOD			
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated			
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	25	U/L	<50	Visible with P-5-P			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	28.0	U/L	17-59	UV with P-5-P			
ALKALINE PHOSPHATASE	84.00	U/L	38-126	p-nitrophenyl phosphate			
PROTEIN, TOTAL	7.70	g/dL	6.3-8.2	Biuret			
ALBUMIN	4.10	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	3.60	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.14		0.9-2.0	Calculated			

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 14



Dr. SHWETA GUPTA
MBBS, MD (Pathology)
Consultant Pathology
SIN No:SE04625400





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:39AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM							
CREATININE	0.80	mg/dL	0.66-1.25	Creatinine amidohydrolase			
UREA	29.40	mg/dL	19-43	Urease			
BLOOD UREA NITROGEN	13.7	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	5.50	mg/dL	3.5-8.5	Uricase			
CALCIUM	9.70	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	4.10	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	136	mmol/L	135-145	Direct ISE			
POTASSIUM	4.3	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	100	mmol/L	98 - 107	Direct ISE			

Page 9 of 14









Age/Gender : 41 Y 10 M 14 D/M

UHID/MR No : SCHI.0000017947 Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:31AM Reported : 10/Feb/2024 11:30AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM	18.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 10 of 14



Dr. SHWETA GUPTA
MBBS, MD (Pathology)
Consultant Pathology
SIN No:SE04625400





Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 10:32AM Reported : 10/Feb/2024 12:58PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	1.07	ng/mL	0.67-1.81	ELFA		
THYROXINE (T4, TOTAL)	7.05	μg/dL	4.66-9.32	ELFA		
THYROID STIMULATING HORMONE (TSH)	1.770	μIU/mL	0.25-5.0	ELFA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 14









Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM

Received : 10/Feb/2024 12:55PM Reported : 10/Feb/2024 01:55PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
TOTAL PROSTATIC SPECIFIC ANTIGEN (tPSA), SERUM	0.930	ng/mL	0-4	CLIA

Page 12 of 14







Age/Gender : 41 Y 10 M 14 D/M UHID/MR No : SCHI.0000017947

Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DETJUXYFG Collected : 10/Feb/2024 10:11AM Received : 10/Feb/2024 11:49AM

Reported : 10/Feb/2024 04:55PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				·
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	′		
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-2	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:UR2279769

Page 13 of 14





: DETJUXYFG

Age/Gender : 41 Y 10 M 14 D/M

UHID/MR No : SCHI.0000017947 Visit ID : SCHIOPV25911

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID

Collected : 10/Feb/2024 10:11AM Received : 10/Feb/2024 11:50AM

Reported : 10/Feb/2024 04:57PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick	
		-		·	
Test Name	Result	Unit	Bio. Ref. Range	Method	

Test Name Result Unit Bio. Ref. Range Method
URINE GLUCOSE(FASTING) NEGATIVE NEGATIVE Dipstick

*** End Of Report ***

Page 14 of 14



